Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple‐treatments meta‐analysis

@article{Taylor2014ComparativeEA,
  title={Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple‐treatments meta‐analysis},
  author={D M Taylor and Victoria R Cornelius and L. A. Smith and Allan H. Young},
  journal={Acta Psychiatrica Scandinavica},
  year={2014},
  volume={130}
}
Treatment of bipolar depression is complicated by variable response and risk of switch to mania. Guidance is informed by the strength of evidence rather than by comparative data. 
Anti‐inflammatory agents in the treatment of bipolar depression: a systematic review and meta‐analysis
TLDR
The objective of the current qualitative and quantitative review was to determine the overall antidepressant effect of adjunctive anti‐inflammatory agents in the treatment of bipolar depression. Expand
Comparative Efficacy And Tolerability Of Lurasidone For The Management Of Bipolar Depression: A Systematic Review And Network Meta-Analysis
TLDR
Results from this network meta-analysis suggest that lurasidone, an approved second-generation antipsychotic for bipolar depression, was as efficacious as quetiapine and olanzapine monotherapies, and was more efficacious than aripiprazole and ziprasidone for the treatment of bipolar depression. Expand
Lurasidone versus typical antipsychotics for schizophrenia
TLDR
This is a protocol for a Cochrane Review (Intervention) to review the efficacy and safety of lurasidone versus typical antipsychotics for adults with schizophrenia or related disorders. Expand
The Treatment of Bipolar Depression: Current Status and Future Perspectives
TLDR
Ketamine represents a major breakthrough, producing rapid reductions in depressive symptoms even in cases of treatment-resistance, but challenges remain in how best to maintain response and reduce unwanted side effects. Expand
Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder
TLDR
The authors conclude that the real question is not whether ADs should or should not be used in bipolar depression, but which patients benefit from these drugs and which ones are impaired. Expand
Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review
TLDR
On the balance of efficacy and tolerability, LTG might be considered a first-line drug for BD, except for acute manic episodes or where rapid symptom control is required, but in terms of efficacy alone, the evidence favours other medications. Expand
Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis.
TLDR
Although no benefits were found in terms of symptoms improvement, response and remission rates, there were clear disadvantages in prescribing higher rather than lower doses of selected SGAs, and data need to be integrated with individual patient characteristics to optimize management of acute bipolar depression. Expand
Tamoxifen for bipolar disorder: Systematic review and meta-analysis
TLDR
Tamoxifen appears to be a promising potential treatment for episodes of mania, and future studies could investigate its effects as an adjunct to dopamine antagonists for improved anti-manic efficacy, and establish its longer term effects on mood, particularly depression and relapse. Expand
A Meta-Analysis of Memantine for Depression.
TLDR
Memantine did not improve the treatment efficacy for depressive symptoms in MDD and BD patients, and long-term study of memantine for depression is required. Expand
Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis
Abstract Objectives: To assess the efficacy and tolerability of lurasidone versus other atypical antipsychotic monotherapy agents in patients with bipolar depression, using a Bayesian networkExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Long‐term antidepressant treatment in bipolar disorder: meta‐analyses of benefits and risks
Objective:  Long‐term antidepressant (AD) treatment for depression in bipolar disorder (BPD) patients is highly prevalent, but its benefits and risks remain uncertain, encouraging this meta‐analysisExpand
Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double‐blind, randomized, placebo‐controlled study
TLDR
To investigate whether the cox‐2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases, a new drug is developed that combines the former and the latter into a single pill. Expand
Previous mood state predicts response and switch rates in patients with bipolar depression
TLDR
The role for antidepressant (AD) agents vs. mood stabilizers has been particularly problematic to ascertain and this work aims to clarify this role. Expand
Lithium response in unipolar versus bipolar depression.
The antidepressant effects of lithium carbonate were evaluated in a group of 52 hospitalized depressed patients, using a longitudinal double-blind design that involved alternating drug and placeboExpand
The use of lithium in affective disorders. I. Acute endogenous depression.
TLDR
After two to three weeks, there was evidence of a moderate to strong antidepressant effect of imipramine, while lithium produced only a weak to mild antidepressant effect. Expand
Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study
TLDR
Olanzapine is effective in the treatment of bipolar I depression but is associated with significant metabolic side effects. Expand
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.
TLDR
Lamotrigine was found effective and safe as add-on treatment to lithium in the acute treatment of bipolar depression. Expand
Divalproex in the treatment of bipolar depression: a placebo-controlled study.
TLDR
These pilot results indicate that divalproex is effective in reducing the symptoms of depression and anxiety in bipolar I, depressed phase, and support the need to perform a larger, multisite study of divalProex treatment for bipolar depression. Expand
Unipolar and bipolar depression: different of the same?
The diagnostic boundary between recurrent unipolar depression and bipolar disorder may not be clear-cut and, further, the symptoms of unipolar depression compared with bipolar depression (althoughExpand
Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials.
TLDR
Lamotrigine monotherapy did not demonstrate efficacy in the acute treatment of bipolar depression in four out of five placebo-controlled clinical studies, but was well tolerated inThe results of five randomized, double-blind, placebo- controlled trials of lamotrigin monotherapy were reported. Expand
...
1
2
3
4
5
...